CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
Junya YamaguchiFumiharu OhkaChalise LushunKazuya MotomuraKosuke AokiKazuhito TakeuchiYuichi NagataSatoshi ItoNobuhiko MizutaniMasasuke OhnoNoriyuki SuzakiSyuntaro TakasuYukio SekiTakahisa KanoKenichi WakabayashiHirofumi OyamaShingo KurahashiKuniaki TanahashiMasaki HiranoHiroyuki ShimizuYotaro KitanoSachi MaedaShintaro YamazakiToshihiko WakabayashiYutaka KondoAtsushi NatsumeRyuta SaitoPublished in: Cancer medicine (2022)
In conclusion, CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in PCNSL. The rapid identification of MYD88 L265P and CD79B Y196 mutations can be helpful not only for the accurate molecular diagnosis of PCNSL but also for the prediction of response to R-MPV.